Description: Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including cancer, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies.
Home Page: www.artelobio.com
ARTL Technical Analysis
505 Lomas Santa Fe
Solana Beach,
CA
92075
United States
Phone:
858 925 7049
Officers
| Name | Title |
|---|---|
| Mr. Gregory D. Gorgas M.B.A. | Pres, CEO, CFO, Treasurer, Sec. & Director |
| Dr. Andrew Yates Ph.D. | Sr. VP & Chief Scientific Officer |
| Dr. Steven D. Reich | Chief Medical Officer |
| Mr. Jason H. Baybutt | Sr. VP of Fin. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.395 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2017-11-14 |
| Fiscal Year End: | August |
| Full Time Employees: | 4 |